Menu

Recent Interviews

Humphrey Hale, CEO, Managing Geologist, Carnavale Resources Ltd.

Humphrey Hale
CEO, Managing Geologist | Carnavale Resources Ltd.
Level 2, Suite 9 389 Oxford Street, WA 6016 Mount Hawthorn (AUS)

info@carnavaleresources.com

Interview Carnavale Resources: Good cards for long-term success


Bill Guy, Chairman, Theta Gold Mines Limited

Bill Guy
Chairman | Theta Gold Mines Limited
Level 35 (ServCorp), Intl Tower One 100 Barangaroo Ave, 2000 NSW Australia (AUS)

info@thetagoldmines.com

+61 2 8046 7584

Interview Theta Gold Mines: This team has already brought 20 mines into production


David Mason, Managing Director, CEO, NewPeak Metals Ltd.

David Mason
Managing Director, CEO | NewPeak Metals Ltd.
Level 27, 111 Eagle Street, QLD 4000 Brisbane (AU)

info@newpeak.com.au

+61 7 3303 0650

Interview New Peak Metals: Many chances for great success


01. June 2021 | 10:05 CET

Defence Therapeutics, CureVac, BioNTech: Vaccine against cancer makes progress

  • Biotechnology
Photo credits: pixabay.com

Biotechnology is the map to the holy grail that needs to be found as quickly as possible for many sick people. When the pandemic broke out last year, it accelerated some developments. For example, mRNA technology, which BioNTech and CureVac had already been researching, was successfully launched as a vaccine technology. It is well known that this can be used to develop effective vaccines against coronaviruses and target diseases such as cancer. BioNTech has this option in mind and holds good cards to succeed with it. The young biotech startup Defence Therapeutics has also recently reported its first successes in the fight against cancer.

time to read: 3 minutes by Nico Popp


 

Author

Nico Popp

At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

About the author


Defence Therapeutics: Accum™ technology brings active ingredients to the target

Defence Therapeutics specializes in targeting active ingredients, such as vaccines or drugs. To do this, the Company uses antibodies that virtually "piggyback" on certain active ingredients. The antibodies can then dock onto a cancer cell, block a receptor there, and carry the active ingredient into the respective cell. Defence Therapeutics has developed Accum™ technology to facilitate this process, enabling active ingredients to be directed even more effectively into affected cells. Specifically, this is achieved by attaching a specific amino acid chain to the antibody, which increases the cell nucleus concentration of the active ingredient used. These so-called Antibody Drug Conjugates (ADC), i.e. the combination of antibody and active ingredient, are considered promising and innovative in research.

As a second mainstay, Defence Therapeutics is developing vaccines. Since these can also be delivered more effectively to the target using ADC technology, the Company's fields of activity complement each other perfectly. Most recently, Defence Therapeutics reported the success of a pre-clinical study on mice. In this study, mice suffering from cancer were treated with the vaccine AccuVAC-D001 developed by Defence Therapeutics. In the end, 70% of the mice with established solid tumors were cured. While it is still a long way from a pre-clinical study in mice to a vaccine for humans, Defence Therapeutics shows that the dream of curing cancer is no longer a utopia. The Company expects the global market for vaccines to grow by 10.7% each year through 2027. Defence Therapeutics is well positioned to benefit from this innovative technology - either as an independent vaccine manufacturer or an acquisition target. Compared to companies like CureVac or BioNTech, the Canadian Company is still in its infancy. For investors, this can be an opportunity.

CureVac: Is there still something to come?

Latecomers have great opportunities, especially when the top dogs stumble. This is currently the case with CureVac. For months, observers have been waiting for the Corona vaccine from Tübingen to finally be launched on the market. Data on its efficacy are still awaited. In parallel, the Swabians are already working with partner Glaxo-SmithKline on a new generation of the vaccine, and this should enter clinical trials in the third quarter. But brash announcements do not yet ensure success.

In January 2020, CureVac had already made a bold announcement of its intention to develop a vaccine. At the time, the Company was ahead of its Mainz-based rival BioNTech. But BioNTech has overtaken CureVac. While the Tübingen-based Company is seen as a Company that wants to do everything very precisely, BioNTech is taking a different approach and wants to get there quickly. Since BioNTech has been approved since the end of 2020 and has already made a name for itself worldwide, the Mainz-based Company's approach must be considered the more successful. In addition, the numerous virus variants make it more difficult for CureVac to conduct clinical trials. When BioNTech was at this stage, the original type of virus was much more widespread. Today, the pandemic situation is much more complex.

BioNTech has its nose in front - Defence Therapeutics as a biotech insider tip

On the stock market, the prices of BioNTech and CureVac have been diverging since March. Since May, the difference has widened even further. The reason is clear: While CureVac is still researching, BioNTech is already earning money. In the long term, however, it cannot be ruled out that CureVac will get back on track - especially the new-generation vaccine could put the Company on the road to success. For both German biotech companies, however, it is equally true that they are already ambitiously valued. In the case of BioNTech, this valuation has a stronger fundamental basis. For investors who want to follow a trend from the very beginning, however, both shares are already unsuitable today. Defence Therapeutics could be an exciting alternative here. The Accum™ technology, designed to deliver active ingredients precisely to malignant cells, and the initial successes in developing a vaccine against cancer make investors sit up and take notice.


Author

Nico Popp

At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

About the author



Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold long or short positions in the aforementioned companies and that there may therefore be a conflict of interest. Apaton Finance GmbH may have a paid contractual relationship with the company, which is reported on in the context of the Apaton Finance GmbH Internet offer as well as in the social media, on partner sites or in e-mail messages. Further details can be found in our Conflict of Interest & Risk Disclosure.


Related comments:

18. June 2021 | 12:49 CET | by André Will-Laudien

CureVac, BioNTech, Novavax, XPhyto Therapeutics - The Covid giants and the sellout!

  • Biotechnology

How quickly the tide can turn in the environment of the Corona pandemic can be seen in the vaccine manufacturers and test providers. BioNTech's share price has been rising steadily since the start of the vaccination campaign in Germany, and minor reports of potential side effects are hardly disturbing. In the case of test provider NanoRepro, the bull market of recent months is turning into a total sell-off, with the share losing over 70%. And then there is the Tübingen-based biotech Company CureVac. Delays in approval and a shock on efficacy send the share down by a whole 50% in one day. We take a closer look at the situation.

Read

15. June 2021 | 13:15 CET | by Nico Popp

CureVac, Cardiol Therapeutics, Bayer: Healthcare for the portfolio

  • Biotechnology

Biotechnology and pharmacology offer us great opportunities. For decades, the world has suffered from a few serious diseases: cancer, cardiovascular disease, Alzheimer's, diabetes and others. Where previously only symptoms were treated, there is now the prospect of a cure thanks to new processes. Even if it still takes a little time to reach market maturity: the innovative companies are already on the market, investors can invest.

Read

07. June 2021 | 09:37 CET | by Stefan Feulner

Bayer, Defence Therapeutics, MorphoSys - A paradigm shift in biotechnology

  • Biotechnology

The search for a vaccine against the Coronavirus brought biotechnology back into the focus of investors last year. Companies such as BioNTech or CureVac were able to multiply in this regard. In 2020, the biotech sector in Germany raised a record sum of EUR 3 billion, and the trend is rising sharply. The fight against incurable diseases and the development of important innovations such as vaccines, cancer therapies, or sustainable products lift the segment into higher realms and offer attractive investment opportunities.

Read